Autolus Therapeutics is working with Cellares to assess automated CAR T manufacturing to support rising demand for its ...

Researchers at the University of Chicago have developed a "universal" chimeric antigen receptor (CAR) platform that offers enhanced safety, adaptability, and the potential to overcome long-standing ...

A personal reflection on the promise and limits of CAR T therapy—its breakthroughs, failures, scientific bottlenecks, and what must change to truly save more lives.

Chimeric antigen receptor natural killer (CAR-NK) cell therapy is emerging as a promising next-generation immunotherapy with ...

A pioneering preclinical study has shown that CAR T cell therapy-a personalized form of immunotherapy used in cancer treatment-could be a highly effective tool against atherosclerosis, the condition ...

Cancer immunotherapy has been transformed by engineered T cells, but those bespoke treatments are slow, expensive, and out of ...

In vivo CAR T-cell therapies could improve access by eliminating complex logistics and reducing costs, making them more accessible to underserved populations. Traditional CAR T-cell therapies face ...

CAR T-cell therapy can be a lifesaving treatment for blood cancers like leukemia and lymphoma. The gene therapy trains a patient’s T cells—white blood cells that play an important role in the immune ...

Capstan Therapeutics scientists demonstrate that lipid nanoparticles can engineer CAR T cells within the body without laboratory cell manufacturing and ex vivo expansion. The method using targeted ...

Members of the CAR T Vision Steering Committee outline key issues around US and EU reimbursement and discuss potential solutions Since their launch in 2017, chimeric antigen receptor T-cell therapies ...

Immune-evading CAR-NK cells maintained a population in mice long enough to eliminate cancer whilst avoiding cytokine release syndrome. Massachusetts Institute of Technology (MIT) and Harvard Medical ...